Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su Belzutifan (MK-6482) in combinazione con Lenvatinib rispetto a Cabozantinib per il trattamento del carcinoma a cellule renali (MK-6482-011)

4 novembre 2026 aggiornato da: Merck Sharp & Dohme LLC

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

Panoramica dello studio

Stato

Attivo, non reclutante

Tipo di studio

Interventistico

Iscrizione (Effettivo)

747

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1120AAT
        • Centro de Urología (CDU) ( Site 0803)
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1280AEB
        • Hospital Británico de Buenos Aires-Oncology ( Site 0801)
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
        • Instituto Alexander Fleming ( Site 0800)
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentina, C1419AHN
        • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Sanatorio Británico-Clinical Oncology Department ( Site 0802)
      • Rosario, Santa Fe Province, Argentina, S2000DSV
        • Sanatorio Parque ( Site 0806)
    • New South Wales
      • St Leonards, New South Wales, Australia, 2065
        • GenesisCare North Shore ( Site 4011)
    • South Australia
      • Elizabeth Vale, South Australia, Australia, 5112
        • Lyell McEwin Hospital ( Site 4004)
    • Victoria
      • Frankston, Victoria, Australia, 3199
        • Peninsula Health Frankston Hospital ( Site 4001)
      • Melbourne, Victoria, Australia, 3000
        • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)
      • Vienna, Austria, 1020
        • Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)
      • Vienna, Austria, 1090
        • Medizinische Universität Wien ( Site 1021)
    • State of Vienna
      • Vienna, State of Vienna, Austria, 1160
        • Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
    • Styria
      • Graz, Styria, Austria, 8036
        • Medizinische Universitätsklinik Graz ( Site 1051)
    • Upper Austria
      • Linz, Upper Austria, Austria, 4020
        • Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)
      • Liège, Belgio, 4000
        • CHU de Liege ( Site 1102)
    • Bruxelles-Capitale, Region de
      • Anderlecht, Bruxelles-Capitale, Region de, Belgio, 1070
        • Institut Jules Bordet ( Site 1103)
      • Brussels, Bruxelles-Capitale, Region de, Belgio, 1200
        • Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)
    • Hainaut
      • Gilly, Hainaut, Belgio, 6060
        • Grand Hopital de Charleroi ( Site 1104)
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgio, 9000
        • UZ Gent ( Site 1100)
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgio, 3000
        • UZ Leuven ( Site 1101)
      • São Paulo, Brasile, 01321-001
        • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)
      • São Paulo, Brasile, 01321-001
        • Hospital Paulistano - Amil Clinical Research ( Site 0308)
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasile, 59151600
        • Liga Norte Riograndense Contra o Cancer ( Site 0313)
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasile, 90110-270
        • Centro Gaucho Integrado de Oncologia ( Site 0304)
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0109)
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Cross Cancer Institute ( Site 0111)
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 6Z8
        • The Moncton Hospital ( Site 0101)
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)
      • Kingston, Ontario, Canada, K7L 2V7
        • Kingston Health Sciences Centre ( Site 0105)
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • CISSS de la Monteregie-Centre ( Site 0103)
      • Québec, Quebec, Canada, G1J 1Z4
        • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0115)
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)
      • Hradec Králové, Cechia, 500 05
        • Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)
    • Brno-mesto
      • Brno, Brno-mesto, Cechia, 656 53
        • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)
    • Praha 4
      • Prague, Praha 4, Cechia, 140 59
        • Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)
    • Praha 5
      • Prague, Praha 5, Cechia, 150 06
        • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)
    • South Bohemian Region
      • České Budějovice, South Bohemian Region, Cechia, 37001
        • Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 2204)
    • Araucania
      • Temuco, Araucania, Chile, 4800827
        • James Lind Centro de Investigacion del Cancer ( Site 0402)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill-Clinical Area ( Site 0400)
    • Antioquia
      • Medellín, Antioquia, Colombia, 050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 0505)
    • Cesar Department
      • Valledupar, Cesar Department, Colombia, 200001
        • Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)
    • Cundinamarca
      • Bogotá, Cundinamarca, Colombia, 111511
        • Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)
    • Santander Department
      • Piedecuesta, Santander Department, Colombia, 681017
        • Fundación Cardiovascular de Colombia ( Site 0501)
      • Seoul, Corea del Sud, 05505
        • Asan Medical Center ( Site 4200)
      • Seoul, Corea del Sud, 06351
        • Samsung Medical Center ( Site 4201)
    • Jeonranamdo
      • Hwasun, Jeonranamdo, Corea del Sud, 58128
        • Chonnam National University Hwasun Hospital-Oncology ( Site 4203)
    • Pirkanmaa
      • Tampere, Pirkanmaa, Finlandia, 33520
        • Tampereen yliopistollinen sairaala ( Site 1801)
    • Southwest Finland
      • Turku, Southwest Finland, Finlandia, 20520
        • TYKS ( Site 1802)
    • Uusimaa
      • Helsinki, Uusimaa, Finlandia, 00290
        • HYKS ( Site 1800)
      • Paris, Francia, 75020
        • Hopital Tenon ( Site 1213)
    • Ain
      • Reims, Ain, Francia, 51726
        • Institut Jean Godinot ( Site 1216)
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Francia, 06189
        • Centre Antoine Lacassagne ( Site 1217)
    • Bas-Rhin
      • Strasbourg, Bas-Rhin, Francia, 67200
        • Hopitaux Universitaires de Strasbourg- Hopital de Hautepierre ( Site 1218)
    • Gironde
      • Bordeaux, Gironde, Francia, 33000
        • CHU de Bordeaux- Hopital Saint Andre ( Site 1209)
    • Haute-Garonne
      • Toulouse, Haute-Garonne, Francia, 31059
        • Institut Claudius Regaud ( Site 1215)
    • Haute-Vienne
      • Limoges, Haute-Vienne, Francia, 87039
        • Clinique Francois Chenieux ( Site 1210)
    • Loire-Atlantique
      • Saint-Herblain, Loire-Atlantique, Francia, 44805
        • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)
    • Maine-et-Loire
      • Angers, Maine-et-Loire, Francia, 49055
        • Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)
      • Berlin, Germania, 10117
        • Charite Universitaetsmedizin Berlin ( Site 1321)
      • Berlin, Germania, 13125
        • HELIOS Klinikum Berlin-Buch ( Site 1311)
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Germania, 79106
        • Klinik fuer Urologie ( Site 1303)
      • Heidelberg, Baden-Wurttemberg, Germania, 69120
        • NCT-Department of Medical Oncology ( Site 1320)
    • Bavaria
      • Nuremberg, Bavaria, Germania, 90419
        • Klinikum Nuernberg Nord ( Site 1300)
    • Hesse
      • Frankfurt am Main, Hesse, Germania, 60590
        • Universitaetsklinikum Frankfurt ( Site 1301)
    • North Rhine-Westphalia
      • Aachen, North Rhine-Westphalia, Germania, 52074
        • Universitaetsklinikum Aachen AOER ( Site 1317)
    • Saarland
      • Homburg/ Saar, Saarland, Germania, 66421
        • Universitaetsklinikum des Saarlandes ( Site 1305)
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Germania, 06120
        • Krankenhaus Martha Maria Halle-Doelau ( Site 1314)
    • Thuringia
      • Erfurt, Thuringia, Germania, 99089
        • Helios Klinikum Erfurt GmbH ( Site 1315)
      • Fukuoka, Giappone, 812-8582
        • Kyushu University Hospital ( Site 5005)
      • Niigata, Giappone, 951-8520
        • Niigata University Medical & Dental Hospital ( Site 5013)
      • Osaka, Giappone, 541-8567
        • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5016)
      • Tokyo, Giappone, 113-8603
        • Nippon Medical School Hospital ( Site 5006)
      • Tokyo, Giappone, 123-8558
        • Tokyo Women's Medical University Adachi Medical Center ( Site 5015)
      • Tokyo, Giappone, 160-8582
        • Keio University Hospital ( Site 5011)
    • Aichi-ken
      • Toyoake, Aichi-ken, Giappone, 470-1192
        • Fujita Health University Hospital ( Site 5003)
    • Chiba
      • Kashiwa, Chiba, Giappone, 2778577
        • National Cancer Center Hospital East ( Site 5000)
      • Sakura, Chiba, Giappone, 285-8741
        • Toho University Sakura Medical Center ( Site 5014)
    • Hokkaido
      • Sapporo, Hokkaido, Giappone, 060-8543
        • Sapporo Medical University Hospital ( Site 5008)
    • Hyōgo
      • Kobe, Hyōgo, Giappone, 650-0047
        • Kobe City Medical Center General Hospital ( Site 5017)
    • Kanagawa
      • Yokohama, Kanagawa, Giappone, 236-0004
        • Yokohama City University Hospital ( Site 5007)
    • Nara
      • Kashihara, Nara, Giappone, 634-0813
        • Nara Medical University Hospital ( Site 5002)
    • Osaka
      • Sakai, Osaka, Giappone, 590-0197
        • Kindai University Hospital ( Site 5010)
      • Suita, Osaka, Giappone, 565-0871
        • The University of Osaka Hospital ( Site 5012)
    • Shizuoka
      • Hamamatsu, Shizuoka, Giappone, 431-3192
        • Hamamatsu University Hospital ( Site 5004)
    • Tokyo
      • Bunkyo-ku, Tokyo, Giappone, 113-8510
        • Institute of Science Tokyo Hospital ( Site 5009)
      • Minato-ku, Tokyo, Giappone, 105-8470
        • Toranomon Hospital ( Site 5001)
      • Thessaloniki, Grecia, 570 01
        • European Interbalkan Medical Center-Oncology Department ( Site 3300)
    • Achaia
      • Pátrai, Achaia, Grecia, 26504
        • UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)
    • Attica
      • Athens, Attica, Grecia, 115 28
        • Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)
      • Athens, Attica, Grecia, 151 25
        • Athens Medical Center ( Site 3303)
      • Chaïdári, Attica, Grecia, 124 62
        • ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)
      • Dublin, Irlanda, D24NR0A
        • Tallaght University Hospital ( Site 3200)
      • Dublin, Irlanda, D07 R2WY
        • Mater Misericordiae University Hospital ( Site 3201)
      • Dublin, Irlanda, D07 R2WY
        • Mater Private Hospital - Dublin ( Site 3202)
      • Arezzo, Italia, 52100
        • Medical Oncology Ospedale San Donato ( Site 1404)
      • Bari, Italia, 70124
        • Azienda Ospedaliera Policlinico di Bari ( Site 1402)
      • Milan, Italia, 20132
        • IRCCS Ospedale San Raffaele ( Site 1409)
      • Milan, Italia, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)
      • Pavia, Italia, 27100
        • Istituti Clinici Scientifici Maugeri Spa ( Site 1403)
      • Roma, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)
      • Terni, Italia, 05100
        • Azienda Ospedaliera S. Maria di Terni ( Site 1401)
      • Verona, Italia, 37126
        • Ospedale Maggiore Borgo Trento ( Site 1408)
    • Forli-Cesena
      • Meldola, Forli-Cesena, Italia, 47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)
    • Milano
      • Rozzano, Milano, Italia, 20089
        • Istituto Clinico Humanitas Research Hospital ( Site 1406)
    • Torino
      • Orbassano, Torino, Italia, 10043
        • Ospedale San Luigi Gonzaga ( Site 1405)
      • Utrecht, Olanda, 3584 CX
        • Universitair Medisch Centrum Utrecht ( Site 1910)
    • Limburg
      • Sittard-Geleen, Limburg, Olanda, 6162 BG
        • Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)
    • North Brabant
      • Breda, North Brabant, Olanda, 4818 CK
        • Amphia Hospital Location Molengracht ( Site 1912)
    • North Holland
      • Amsterdam, North Holland, Olanda, 1066 CX
        • Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)
    • Provincie Friesland
      • Leeuwarden, Provincie Friesland, Olanda, 8934 AD
        • Medisch Centrum Leeuwarden ( Site 1905)
    • South Holland
      • Rotterdam, South Holland, Olanda, 3015 GD
        • Erasmus MC ( Site 1913)
      • Schiedam, South Holland, Olanda, 3118 JH
        • Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)
      • The Hague, South Holland, Olanda, 2545 AA
        • Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polonia, 60-569
        • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-796
        • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polonia, 31-115
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 2403)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)
    • Aberdeen City
      • Aberdeen, Aberdeen City, Regno Unito, AB25 2ZN
        • Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)
    • Bath And North East Somerset
      • Bath, Bath And North East Somerset, Regno Unito, BA1 3NG
        • Royal United Hospital Bath England ( Site 3108)
    • England
      • Nottingham, England, Regno Unito, NG5 1PF
        • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)
    • Essex
      • Southend, Essex, Regno Unito, SS0 0RY
        • Southend University Hospital ( Site 3112)
    • London, City of
      • London, London, City of, Regno Unito, W6 8RF
        • Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)
      • Northwood, London, City of, Regno Unito, HA6 2RN
        • Mount Vernon Cancer Centre ( Site 3101)
    • Somerset
      • Taunton, Somerset, Regno Unito, TA1 5DA
        • Musgrove Park Hospital ( Site 3103)
    • Wales
      • Swansea, Wales, Regno Unito, SA2 8QA
        • Singleton Hospital ( Site 3111)
    • Cluj
      • Cluj-Napoca, Cluj, Romania, 400015
        • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)
      • Cluj-Napoca, Cluj, Romania, 400015
        • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)
    • Dolj
      • Craiova, Dolj, Romania, 200542
        • Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)
    • Ivanovo Oblast
      • Ivanovo, Ivanovo Oblast, Russia, 153040
        • Ivanovo Regional Oncology Dispensary ( Site 2616)
    • Moscow
      • Moscow, Moscow, Russia, 119285
        • FSBI United Hospital with Polyclinic ( Site 2613)
      • Moscow, Moscow, Russia, 125130
        • SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)
    • Moscow Oblast
      • Krasnogorsk, Moscow Oblast, Russia, 143442
        • MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
      • Moscow, Moscow Oblast, Russia, 121205
        • Hadassah Medical-Oncology department ( Site 2609)
    • Volgograd Oblast
      • Volzhsky, Volgograd Oblast, Russia, 404120
        • Volgograd Regional Uronephrological Center ( Site 2615)
    • Yaroslavl Oblast
      • Yaroslavl, Yaroslavl Oblast, Russia, 150054
        • Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)
      • Barcelona, Spagna, 08035
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)
      • Barcelona, Spagna, 08036
        • Hospital Clinic i Provincial ( Site 1500)
      • Barcelona, Spagna, 08041
        • Hospital Santa Creu i Sant Pau ( Site 1501)
      • Madrid, Spagna, 28009
        • Hospital General Universitario Gregorio Maranon ( Site 1505)
      • Madrid, Spagna, 28040
        • Hospital Clinico San Carlos... ( Site 1504)
      • Seville, Spagna, 41013
        • Hospital Virgen del Rocio ( Site 1503)
    • La Coruna
      • A Coruña, La Coruna, Spagna, 15006
        • Complejo Hospitalario Universitario A Coruna ( Site 1502)
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spagna, 28041
        • Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)
    • Arizona
      • Chandler, Arizona, Stati Uniti, 85224
        • Ironwood Cancer & Research Centers ( Site 0077)
    • California
      • Los Angeles, California, Stati Uniti, 90048
        • Cedars Sinai Medical Center ( Site 0027)
      • Los Angeles, California, Stati Uniti, 90404
        • UCLA Hematology/Oncology - Santa Monica ( Site 0048)
      • Orange, California, Stati Uniti, 92868
        • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
      • Orange, California, Stati Uniti, 92868
        • University of California, Irvine ( Site 0029)
      • Santa Monica, California, Stati Uniti, 90404
        • Providence Saint John's Health Center ( Site 0083)
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20007
        • Georgetown University Medical Center ( Site 0006)
    • Florida
      • Orlando, Florida, Stati Uniti, 32806
        • Orlando Health, Inc. ( Site 0035)
      • Orlando, Florida, Stati Uniti, 32804
        • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)
    • Georgia
      • Athens, Georgia, Stati Uniti, 30607
        • University Cancer & Blood Center, LLC ( Site 0057)
      • Atlanta, Georgia, Stati Uniti, 30322
        • Emory University Hospital ( Site 0012)
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60607
        • Rush University Medical Center ( Site 0040)
      • Peoria, Illinois, Stati Uniti, 61615
        • Illinois Cancer Care, PC ( Site 0008)
    • Indiana
      • Fort Wayne, Indiana, Stati Uniti, 46845
        • Parkview Cancer Institute ( Site 0088)
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40207
        • Norton Cancer Institute - St. Matthews ( Site 0065)
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Tulane University School of Medicine ( Site 0098)
    • Massachusetts
      • Burlington, Massachusetts, Stati Uniti, 01805
        • Lahey Hospital & Medical Center ( Site 0090)
    • Michigan
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Cancer & Hematology Centers of Western Michigan ( Site 0018)
    • Minnesota
      • Saint Louis Park, Minnesota, Stati Uniti, 55426
        • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
    • Mississippi
      • Jackson, Mississippi, Stati Uniti, 39213
        • University of Mississippi Medical Ctr ( Site 0037)
    • Nebraska
      • Lincoln, Nebraska, Stati Uniti, 68516
        • Cancer Partners of Nebraska ( Site 0086)
    • New Jersey
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Rutgers Cancer Institute of New Jersey ( Site 0078)
    • New York
      • Lake Success, New York, Stati Uniti, 11042
        • R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center ( Site 0055)
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Levine Cancer Institute ( Site 0004)
      • Durham, North Carolina, Stati Uniti, 27710
        • Duke Cancer Institute ( Site 0096)
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18103
        • Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
    • Texas
      • Dallas, Texas, Stati Uniti, 75235
        • University of Texas, Southwestern Medical Center ( Site 0015)
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)
    • Vermont
      • Burlington, Vermont, Stati Uniti, 05401
        • University of Vermont Medical Center ( Site 0001)
    • Virginia
      • Roanoke, Virginia, Stati Uniti, 24014
        • Blue Ridge Cancer Care - Roanoke ( Site 0043)
    • Washington
      • Seattle, Washington, Stati Uniti, 98109
        • Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
      • Wenatchee, Washington, Stati Uniti, 98801
        • Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)
    • Canton Ticino
      • Bellinzona, Canton Ticino, Svizzera, 6500
        • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
    • Canton of Geneva
      • Geneva, Canton of Geneva, Svizzera, 1211
        • Hopitaux Universitaires de Geneve HUG ( Site 1602)
    • Canton of Zurich
      • Zurich, Canton of Zurich, Svizzera, 8001
        • Universitaetsspital Zuerich ( Site 1601)
    • Kanton Graubünden
      • Chur, Kanton Graubünden, Svizzera, 7000
        • Kantonsspital Graubuenden ( Site 1600)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC)
  • Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria as assessed by local study investigator
  • Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization
  • Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
  • Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC
  • A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib
  • A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm
  • Adequately controlled blood pressure
  • Adequate organ function

Exclusion Criteria:

  • A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
  • Known central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Clinically significant cardiac disease within 6 months of first dose of study intervention
  • Prolongation of corrected QT interval (QTc) interval to >480 ms.
  • Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable
  • Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
  • Moderate to severe hepatic impairment
  • History of significant bleeding within 3 months before randomization.
  • History of solid organ transplantation
  • Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
  • Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption)
  • Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations
  • Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization
  • Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor
  • Prior treatment with lenvatinib
  • Prior treatment with cabozantinib
  • Currently participating in a study of an investigational agent or using an investigational device
  • Active infection requiring systemic therapy
  • History of human immunodeficiency virus (HIV) infection
  • History of hepatitis B or known active hepatitis C infection

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Belzutifan + Lenvatinib

Participants received daily oral dose of belzutifan 120 mg and lenvatinib 20 mg until progressive disease or discontinuation.

Oral administration

Altri nomi:
  • MK-6482
  • PT2977
  • WELIREG™

Oral administration

Altri nomi:
  • E7080
  • Levima
  • MK-7902
Comparatore attivo: Cabozantinib

Participants received daily oral dose of cabozantinib 60 mg until progressive disease or discontinuation.

Oral administration

Altri nomi:
  • BMS-907351
  • Cabometix
  • Cometriq
  • XL184

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Lasso di tempo: Up to approximately 34 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented.

Up to approximately 34 months
Overall Survival (OS)
Lasso di tempo: Up to approximately 44 months

OS is defined as time from randomization to death due to any cause.

Up to approximately 44 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Lasso di tempo: Up to approximately 24 months

ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.

Up to approximately 24 months
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Lasso di tempo: Up to approximately 44 months

For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented.

Up to approximately 44 months
Number of Participants Who Experienced One or More Adverse Events (AEs)
Lasso di tempo: Up to approximately 44 months

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 44 months
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Lasso di tempo: Up to approximately 44 months

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 44 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 febbraio 2021

Completamento primario (Effettivo)

2 febbraio 2026

Completamento dello studio (Stimato)

11 febbraio 2027

Date di iscrizione allo studio

Primo inviato

9 ottobre 2020

Primo inviato che soddisfa i criteri di controllo qualità

9 ottobre 2020

Primo Inserito (Effettivo)

14 ottobre 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 6482-011
  • MK-6482-011 (Altro identificatore: MSD)
  • jRCT2031210311 (Altro identificatore: jRCT(Japan Registry of Clinical Trials))
  • 2020-002075-35 (Numero EudraCT)
  • U1111-1302-2815 (Identificatore di registro: UTN)
  • 2024-510620-39-00 (Identificatore di registro: EU CT)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi